摘要
目的:探讨玻璃体腔注射雷珠单抗对增殖性糖尿病视网膜病变患者手术后视力的影响。方法:选取我院眼科欲行微创玻璃体切割术治疗的增殖性糖尿病视网膜病变患者110例,随机分为两组,实验组患者55例,96眼,对照组55例,102眼,两组患者均行微创玻璃体切割术,实验组患者在手术前给予雷珠单抗。观察并比较两组患者治疗前后血管内皮生长因子(VEGF)、视力水平以及患者手术时间、手术出血情况、患者临床治疗有效率。结果:与治疗前相比,治疗后两组患者的VEGF水平均下降,视力水平均升高,差异具有统计学意义(P<0.05);与对照组相比,实验组患者的VEGF水平较低,视力水平较高,差异具有统计学意义(P<0.05);与对照组相比,实验组患者的手术时间较短、手术出血率较低、患者临床治疗有效率较高,差异具有统计学意义(P<0.05)。结论:玻璃体腔注射雷珠单抗能够明显改善增殖性糖尿病视网膜病变患者手术后VEGF以及视力水平,患者手术的出血率较低,临床疗效较好。
Objective： To investigate the effect of intravitreal injection of monoclonal antibody on the postoperative visual acuity in patients with proliferative diabetic retinopathy. Methods： 110 patients with proliferative diabetic retinopathy treated by minimally invasive incision treatment of vitreous body were randomly divided into two groups,55 cases,96 eyes of patients in the experimental group,the control group of 55 cases,102 eyes of two patients underwent minimally invasive vitreous body incision,the patients in the experimental group before surgery given ranibizumab. The vascular endothelial growth factor（ VEGF）,visual acuity,the operation time,bleeding,and the efficiency of clinical treatment between the two groups before and after treatment were observed and compared. Results： Compared with before treatment,the level of VEGF decreased and visual acuity increased in the two groups after treatment,and the difference was statistically significant（ P〈0.05）; Compared with the control group,the patients in the experimental group had lower VEGF levels and higher visual acuity,and the difference was statistically significant（ P〈0.05）; Compared with the control group,the operation time of the experimental group was shorter,the rate of operation bleeding was lower,and the effective rate of clinical treatment was higher,the difference was statistically significant（ P〈0.05）. Conclusion： Intravitreal injection can significantly improve the postoperative VEGF and visual acuity in patients with proliferative diabetic retinopathy,the bleeding rate is low,and the clinical effect is better.
作者
张永红
张晓湄
付鹏
ZHANG Yonghong ZHANG Xiaomei FU Peng(Liuzhou People＇s Hospital, Guangxi Liuzhou 545006, Chin)
出处
《河北医学》
CAS
2017年第7期1105-1108,共4页
Hebei Medicine
基金
广西自然科学基金项
(编号:2010GXNSFB013090)
关键词
雷珠单抗
增殖性糖尿病视网膜病变
视力
Monoclonal antibody
Proliferative diabetic retinopathy
Vision
